Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients
Authors:
- Alberto BorghettiABAlberto Borghetti
- Gianmaria BaldinGBGianmaria Baldin
- Amedeo CapettiACAmedeo Capetti
- Gaetana SterrantinoGSGaetana Sterrantino
- Stefano RusconiSRStefano Rusconi
- Alessandra LatiniAlessandra Latini
- Andrea GiacomettiAGAndrea Giacometti
- Giordano MadedduGiordano Madeddu
- Chiara PicarelliCPChiara Picarelli
- Ramona De MarcoRMRamona De Marco
- Maria V. CossuMaria V. Cossu
- Filippo LagiFLFilippo Lagi
Open Access
- 28 January 2017
- journal article
- editorial
- Published by Wolters Kluwer Health in AIDS
- Vol. 31 (3) , 457-459
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practiceAIDS, 2016
- Switching regimens in virologically suppressed HIV‐1‐infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)‐containing regimensHIV Medicine, 2016
- Brief ReportJAIDS Journal of Acquired Immune Deficiency Syndromes, 2015
- 48-Week Efficacy and Safety of Dolutegravir Relative to Commonly Used Third Agents in Treatment-Naive HIV-1–Infected Patients: A Systematic Review and Network Meta-AnalysisPLOS ONE, 2014
- Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING studyThe Lancet, 2013